EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Results of two EORTC studies have been published in NEJM and the Lancet Oncology
21 Sep 2022
EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma
5 Aug 2022
In Memoriam: Dr Martin Charles Mihm
27 Jul 2022
Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma
24 May 2022
PRESS RELEASE: European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
29 Jun 2021
EORTC Melanoma Group changing daily practice for cancer patients
28 Sep 2020
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
19 Sep 2020